Rezolute, Inc. RZLT
At closeNov 4, 2026, 4:01 PM EST
After hours · Nov 4, 4:01 PM ET
- YTD
- +67.80%
- 1 year
- -55.51%
- Market cap
- 383.02M
- EPS (ttm)
- -0.75
- Shares out
- 57.94M
- Forward P/E
- -3.42
- YTD return
- +67.80%
- 1-year return
- -55.51%
- Volume
- 1.07M
- Avg volume
- 1.48M
- Open
- 4.12
- Previous close
- 4.01
- Day's range
- 3.95 – 4.34
- 52-week range
- 1.07 – 11.46
- Beta
- 1.19
- Price target
- 13.00 (+228.3%)
2Y -1.49 (-27.39%)
Key statistics
- Enterprise value
- 192.07M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.95
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -31.00M
- Total cash
- 126.87M
- Total debt
- 2.23M
- Return on equity
- -57.73%
- Short % of float
- 2.84%
- 50-day average
- 5.12
- 200-day average
- 4.17
Analyst view
- Target (low)
- 8.00
- Target (mean)
- 13.00
- Target (high)
- 16.00
- Strong buy3
- Buy7
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.26.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 5, 2024 | Wedbush | init | — | Outperform |
| Aug 6, 2024 | Maxim Group | main | Buy | Buy |
| Aug 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 17, 2024 | BTIG | init | — | Buy |
| Jun 4, 2024 | Craig-Hallum | init | — | Buy |
About Rezolute, Inc.
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. The company's lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- rezolutebio.com
News
Rezolute (NASDAQ:RZLT) Share Price Breaks Above 200 Day Moving Average – Here’s What Happened 
Rezolute to Participate in Upcoming Investor Conferences 
Rezolute (NASDAQ:RZLT) Stock Price Crosses Below 200-Day Moving Average – What’s Next? 
Rezolute Completes Enrollment In Open-Label Phase 3 Study Of Ersodetug In Tumor HI; Topline Data Expected In Mid-December 2026 
Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism 
Rezolute, Inc. (NASDAQ:RZLT) Stock Now Rated “Moderate Buy” by Sell-Side Analysts 
This NetApp Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday 
Lake Street Maintains Buy on Rezolute, Raises Price Target to $12 
Citizens Maintains Market Outperform on Rezolute, Raises Price Target to $15 
This Boyd Gaming Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Your note
Sign in to keep a note on RZLT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ELAM NEVAN C | Chief Executive Officer | Purchase | Feb 25, 2024 | 7,817 |
| EVANS DARON | Chief Financial Officer | Purchase | Dec 17, 2024 | 232,900 |
| HOGENHUIS WLADIMIR | Director | Purchase | Sep 23, 2024 | 41,767 |
| KIM YOUNG-JIN | Director | Purchase | Mar 6, 2024 | 6,058,070 |
| ROBERTS BRIAN KENNETH | Officer | Purchase | Jun 13, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vivo Capital, LLC | 33.23% | 2,797,704 | 12.42M | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 30.61% | 2,577,121 | 11.44M | Sep 29, 2024 |
| Vanguard Group Inc | 22.95% | 1,932,057 | 8.58M | Sep 29, 2024 |
| Blackstone Inc | 20.73% | 1,744,740 | 7.75M | Sep 29, 2024 |
| Affinity Asset Advisors, Llc | 20.19% | 1,700,000 | 7.55M | Sep 29, 2024 |
| Altium Capital Management, LP | 20.19% | 1,700,000 | 7.55M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes Kaufmann Fund | 45.44% | 3,825,000 | 16.98M | Jul 30, 2024 |
| Federated Hermes Kaufmann Small Cap Fund | 45.29% | 3,812,860 | 16.93M | Jul 30, 2024 |
| Vanguard Total Stock Market Index Fund | 12.85% | 1,081,601 | 4.80M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 9.06% | 762,525 | 3.39M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 3.10% | 260,618 | 1.16M | Oct 30, 2024 |
| iShares Micro Cap ETF | 1.22% | 103,090 | 457.72K | Oct 30, 2024 |